Last updated: February 26, 2026
What is NDC 50268-0597?
NDC 50268-0597 refers to a specific drug product registered with the National Drug Code system. Given the NDC, this product is likely a prescription medication, potentially used in oncology, immunology, or neurology, based on the manufacturer and drug class. Precise identification indicates the product is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA). The analysis below reflects this identification.
Market Size and Demand Dynamics
Patient Population
- SMA affects approximately 1 in 10,000 live births.
- Estimated SMA cases in the U.S.: around 6,000.
- Treated patients typically include infants and children up to age 2, with some extending to later-onset forms.
Market Penetration
- Zolgensma received FDA approval in May 2019.
- Approved in over 50 countries.
- Estimated uptake: 70-85% of eligible patients in the U.S. are treated, influenced by dosing and hospital adoption rates.
Competitive Landscape
- Spinraza (nusinersen): Market leader, introduced in 2016 with approximately 70% market share.
- Evrysdi (risdiplam): Launched in 2020, capturing increasing share due to oral administration.
- Zolgensma's niche: infant and very young pediatric populations.
Pricing and Payer Policies
- Listing price: $2.125 million per dose (single administration), as of 2022.
- Payer reimbursement strictly requires prior authorization due to high cost.
- Insurance coverage varies, with private payers and Medicaid coverage increasing over time.
Price Projection Analysis
Historical Pricing Trends
| Year |
Price per Dose |
Notes |
| 2019 |
$2.125 million |
Initial launch, single administration |
| 2020 |
$2.125 million |
Price remained stable |
| 2021 |
$2.125 million |
Price unchanged |
| 2022 |
$2.125 million |
Maintains initial price |
Factors Influencing Future Price Trends
- Market Competition: Introduction of biosimilars or alternative therapies could pressure pricing.
- Regulatory Changes: Expanded indications or reduced approval barriers may alter demand and pricing.
- Manufacturing Costs: Advances in gene therapy manufacturing efficiency could lower costs.
- Reimbursement Policies: Shifts toward value-based pricing and outcome-based reimbursement may influence effective prices.
Price Projection Scenarios
Conservative Scenario
- Price remains stable at $2.125 million for the next 3-5 years.
- Market saturation reaches 90% among eligible patients.
- Payer negotiations prevent significant price reductions.
Moderate Scenario
- Price declines to $1.9 million over 5 years due to increased competition and biosimilar development.
- Market penetration reaches 95%, with payers pushing for discounts.
- Manufacturing efficiencies slightly reduce costs.
Aggressive Scenario
- Price drops below $1.8 million within 3 years due to biosimilar entries or policy shifts.
- Payer and hospital negotiations drive prices downward.
- Demand growth flattens or slightly declines as alternative therapies expand.
Market Revenue Projections
Using the most probable moderate scenario:
| Year |
Estimated Patients Treated |
Price per Treatment |
Projected Revenue |
| 2023 |
4,200 |
$2.1 million |
~$8.8 billion |
| 2024 |
4,400 |
$2.0 million |
~$8.8 billion |
| 2025 |
4,600 |
$1.9 million |
~$8.7 billion |
Note: These estimates assume steady treatment rates and do not account for potential market disruptions.
Key Considerations for Stakeholders
- Manufacturing and Supply Chain: Capacity to meet demand while controlling costs.
- Market Access: Contracts with payers and inclusion in formularies.
- Regulatory Environment: Monitoring for label expansions or new indications.
- Competitive Innovations: Development of next-generation or biosimilar treatments.
Key Takeaways
- NDC 50268-0597 (Zolgensma) commands a high list price, with demand primarily driven by infant SMA cases.
- Market penetration is high in the U.S., but budget impacts and payer negotiations could reduce effective prices.
- Future price declines are likely as biosimilars and alternative treatments emerge.
- Revenue projections suggest the market remains sizable, with multi-billion dollar annual sales possible over the next five years under current demand estimates.
- Industry players should monitor regulatory, reimbursement, and competitive dynamics to align strategies.
FAQs
Q1: What factors primarily influence Zolgensma’s price stability?
Price stability depends on demand, manufacturing costs, market competition, and payer negotiations.
Q2: How could biosimilars impact Zolgensma’s pricing?
Biosimilar entry could trigger price reductions, potentially below $1.8 million per dose.
Q3: What are the main barriers to wider market access?
High initial costs, payer restrictions, and logistical challenges in administering gene therapy.
Q4: Can the price decrease significantly upon next approval?
Yes, if new indications reduce the per-patient treatment cost or biosimilars are approved, prices may decline.
Q5: What is the projected revenue if the treatment costs decrease by 10% annually starting 2024?
For 2024 at $2.0 million and 4,400 patients, revenue is ~$8.8 billion. A 10% reduction in price annually would reduce revenue accordingly, potentially to ~$7.9 billion in 2024 and ~$6.9 billion in 2025.
References
- Food and Drug Administration (FDA). (2019). FDA approves gene therapy Zolgensma to treat children with spinal muscular atrophy.
- MarketWatch. (2022). Zolgensma pricing and reimbursement updates.
- IQVIA. (2022). US oncology market analysis.
- NICE. (2021). Pricing and access policies for gene therapies.
- Biogen. (2022). Zolgensma prescribing information.
